119446-68-3CC1COC(Cn2cncn2)(c2ccc(Oc3ccc(Cl)cc3)cc2Cl)O1BQYJATMQXGBDHF-UHFFFAOYSA-NDifenoconazole is a member of the class of dioxolanes that is 1,3-dioxolane substituted at position 2 by 2-chloro-4-(4-chlorophenoxy)phenyl and 1,2,4-triazol-1-ylmethyl groups. A broad spectrum fungicide with novel broad-range activity used as a spray or seed treatment. It is moderately toxic to humans, mammals, birds and most aquatic organisms. It has a role as a xenobiotic, an EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor, an environmental contaminant and an antifungal agrochemical. It is an aromatic ether, a member of triazoles, a dioxolane, a cyclic ketal, a conazole fungicide and a triazole fungicide.
119446-68-3Agrochemicals -> Pesticide active substances
Active substance -> EU Pesticides database: Approved
Pesticides -> Fungicides
Environmental transformation -> Pesticides (parent, predecessor)
Fungicides
Pesticide (Difenoconazole) -> USDA PDB
Odorless
Sweetish odor
White crystalline solid
White to light beige crystals
Beige-grayish crystalline solid
In water, 15 mg/L at 25 °C
In water, 5 mg/L at 20 °C
Very soluble in most organic solvents
Soluble in acetone, dichloromethane, toluene, methanol and ethyl acetate >500 g/L, hexane 3 g/L, octanol 110 g/L (at 25 °C)
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
Warning
H302: Harmful if swallowed [Warning Acute toxicity, oral]
P203, P264, P264+P265, P270, P273, P280, P301+P317, P305+P351+P338, P318, P330, P337+P317, P391, P405, and P501 (click each P-code to see the statement)
Warning
H302+H332 (29.5%): Harmful if swallowed or if inhaled [Warning Acute toxicity, oral; acute toxicity, inhalation]
P261, P264, P264+P265, P270, P271, P273, P280, P301+P317, P304+P340, P305+P351+P338, P317, P330, P337+P317, P391, and P501 (click each P-code to see the statement)
Regulation (EC) No 396/2005 (amended)
Difenoconazole is listed in the dataset of EPA Human Health Benchmarks for Pesticides under the Safe Drinking Water Act (40 eCFR 141)
2008/69, Reg. (EU) 2018/1796, Reg. (EU) 2019/1589, Reg. (EU) 2020/1511, Reg. (EU) 2021/1449, Reg. (EU) 2022/1480, Reg. (EU) 2023/2592, Reg. (EU) 2025/2316, Reg. (EU) No 1100/2011, Reg. (EU) No 540/2011
Difenoconazole: Does not have an individual approval but may be used under an appropriate group standard
Tolerances are established for residues of difenoconazole, including its metabolites and degradates, in or on the commodities in the following table. Compliance with the tolerance levels specified below is to be determined by measuring only difenoconazole, 1-[2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazole, in or on the following raw agricultural commodities:[Table#8407]
Tolerances are established for residues of difenoconazole, including its metabolites and degradates, in the commodities in the table below. Compliance with the tolerance levels specified below is to be determined by measuring the sum of difenoconazole, 1-[2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazole, and its metabolite, CGA-205375, 1-[2-chloro-4-(4-chloro-phenoxy)phenyl]-2-[1,2,4]triazol-1-yl-ethanol, calculated as the stoichiometric equivalent of difenoconazole, in the following commodities:[Table#8408]
/Difenoconazole/ is applied by foliar spray or seed treatment and acts by interference with the synthesis of ergosterol in the target fungi by inhibition of the 14alpha-demethylation of sterols, which leads to morphological and functional changes in the fungal cell membrane.
After 14 days of [4-chloro-phenoxy-U-(14)C]difenoconazole at a dose of at 0.5 mg/kg bw per day, ... the depletion of radioactive residues from tissues was moderately fast. Assuming first-order kinetics and monophasic depletion kinetics for the depuration of radiolabel from tissues, the half-lives ranged typically from 4-6 days. Depletion was more rapid in the liver, kidneys and pancreas, with half-lives of 1-3 days, and slower in fat, with a half-life of 9 days.
Metabolites were isolated from the urine and feces of male and female rats given [(14)C-phenyl] difenoconazole or [(14)C-triazole]difenoconazole as single oral dose at 0.5 or 300 mg/kg bw, or 0.5 mg/kg bw after pre-treatment with 14 daily oral doses of unlabelled difenoconazole at 0.5 mg/kg bw. Balance data for the phenyl and triazole ring labels ... showed that > 97% of the radiolabel in all cases was excreted with > 78% in all cases eliminated in the feces. Three main metabolites, A, B and C, were isolated from feces and together accounted for an average of 68% of the administered dose. Metabolite B (hydroxy-CGA 169374) was hydroxylated in the outer phenyl ring and spectral analysis showed that that it comprised two isomers, one with a rearrangement of the chlorine on the outer phenyl ring, attributed to a mechanism analogous to an NIH shift. Metabolite C (CGA 205375) was the hydroxyl product of cleavage of the dioxolane ring from the difenoconazole molecule and was present only in the feces of rats given the higher dose. Metabolite A (hydroxy-CGA 205375) was the outer phenyl-ring hydroxylated product of metabolite C and comprised two diastereoisomers, as described for metabolite B. The profile of urinary metabolites was more complex and showed more variability between the two radiolabelled forms. Free 1,2,4-triazole was identified in male urine, accounting for less than 10% of the administered dose and represented cleavage of the alkyl bridge between the ring systems. Other urinary metabolites included metabolite C, its sulfate conjugate, ring-hydroxylated metabolite C and its sulfate conjugate, as well as an hydroxyacetic acid metabolite of the chlorophenoxy-chlorophenyl moiety, all of which were present in minor quantities, each representing less than 3% of the administered dose. One metabolite CGA 189138 (chlorophenoxy-chlorobenzoic acid) was also isolated from the liver. The difenoconazole molecule was therefore extensively metabolized, although with limited cleavage of the triazole and dioxolane rings. The extensive biliary elimination observed was consistent with the major metabolites being of relatively high molecular mass.
현재 필터 조건에 해당하는 반응 기록이 없습니다.
불러오는 중…
DTXSID4032372CHEMBL466426CHEBI:81760VP: 1.2X10-7 Pa at 20 °C (9.0X10-10 mm Hg)
2.5X10-10 mm Hg at 25 °C (3.3X10-5 mPa)
New Active Ingredients ... includes chemicals not previously registered as pesticides, as well as pesticide active ingredients initially registered after November 1, 1984 and that currently have active product registrations. By law, these pesticides must meet new safety standards, such as those described in the Food Quality Protection Act of 1996 and, if new safety standards are met, will be reviewed again on a 15-year cycle. Difenoconazole is designated by EPA as a New Pesticide Active Ingredient. Active Ingredient Number: 128847; Type of Pesticide: conventional - fungicide; Use Site: food use/wheat grain; Year: 1994.
Acute Tox. 4 (100%)
Acute toxicity (Oral) - Category 4
Acute toxicity (Oral) - Category 4
Carc. 2
SRP: Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in air, soil or water; effects on animal, aquatic and plant life; and conformance with environmental and public health regulations. If it is possible or reasonable use an alternative chemical product with less inherent propensity for occupational harm/injury/toxicity or environmental contamination.
SRP: Wastewater from contaminant suppression, cleaning of protective clothing/equipment, or contaminated sites should be contained and evaluated for subject chemical or decomposition product concentrations. Concentrations shall be lower than applicable environmental discharge or disposal criteria. Alternatively, pretreatment and/or discharge to a permitted wastewater treatment facility is acceptable only after review by the governing authority and assurance that "pass through" violations will not occur. Due consideration shall be given to remediation worker exposure (inhalation, dermal and ingestion) as well as fate during treatment, transfer and disposal. If it is not practicable to manage the chemical in this fashion, it must be evaluated in accordance with EPA 40 CFR Part 261, specifically Subpart B, in order to determine the appropriate local, state and federal requirements for disposal.
Open dumping is prohibited. Wastes resulting from the use of this product may be disposed of on site or at an approved waste disposal facility.
Avoid contact with skin, eyes, or clothing. Avoid breathing vapor or spray mist. ... Wash thoroughly with soap and water after handling and before eating, drinking, chewing gum, using tobacco or using the toilet. Remove contaminated clothing and wash before reuse.
User should remove clothing/personal protective equipment (PPE) immediately if pesticide gets inside. Then wash thoroughly and put on clean clothing. User should remove PPE immediately after handling this product. Wash thoroughly and change into clean clothing as soon as possible. Wash outside of gloves before removing.
This pesticide is toxic to fish, mammals, and aquatic invertebrates. Drift and runoff may be hazardous to aquatic, estuarine, and marine organisms in water adjacent to treated areas. For terrestrial uses: Do not apply directly to water, or to areas where surface water is present or intertidal areas below the mean high water mark. Do not contaminate water when disposing of equipment washwater or rinsate. DO NOT discharge effluent containing this product into lakes, streams, ponds, estuaries, oceans, or other waters unless in accordance with the requirements of a National Pollutant Discharge Elimination System (NPDES) permit and the permitting authority has been notified in writing prior to discharge. DO NOT discharge effluent containing this product to sewer systems without previously notifying the local sewage treatment plant authority. For guidance contact your State Water Board or Regional Office of the EPA.
Avoid skin contact and vapor inhalation.
For more Preventive Measures (Complete) data for Difenoconazole (6 total), please visit the HSDB record page.
Tolerances are established for residues of difenoconazole, including its metabolites and degradates, in or on the commodities in the following table. Compliance with the tolerance levels specified below is to be determined by measuring only difenoconazole, 1-[2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazole, in or on the following raw agricultural commodities:[Table#8405]
Tolerances are established for residues of difenoconazole, including its metabolites and degradates, in the commodities in the table below. Compliance with the tolerance levels specified below is to be determined by measuring the sum of difenoconazole, 1-[2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazole, and its metabolite, CGA-205375, 1-[2-chloro-4-(4-chloro-phenoxy)phenyl]-2-[1,2,4]triazol-1-yl-ethanol, calculated as the stoichiometric equivalent of difenoconazole, in the following commodities:[Table#8406]
Wear long-sleeved shirt and long pants, socks, shoes, protective eyewear and chemical resistant gloves when handling.
Long-sleeved shirt and long pants. Protective eyewear. Rubber gloves for undiluted formulation Score; boots.
LD50; Species: Serinus canaria (Island Canary) age 9.5 months; oral via capsule >2,000 mg/kg[USEPA, Office of Pesticide Programs; Pesticide Ecotoxicity Database (2000) on 1-[[2-
LC50; Species: Colinus virginianus (Northern Bobwhite Quail) age 14 days; dietary 4760 ppm for 9 days (95% confidence interval: 4103-5522 ppm)[USEPA, Office of Pesticide Programs; Pesticide Ecotoxicity Database (2000) on 1-[[2-
LC50; Species: Anas platyrhynchos (Mallard Duck) age 8 days; dietary >5000 ppm for 11 days[USEPA, Office of Pesticide Programs; Pesticide Ecotoxicity Database (2000) on 1-[[2-
LD50; Species: Anas platyrhynchos (Mallard Duck) age 30 weeks; oral via capsule >2150 mg/kg[USEPA, Office of Pesticide Programs; Pesticide Ecotoxicity Database (2000) on 1-[[2-
For more Ecotoxicity Values (Complete) data for Difenoconazole (25 total), please visit the HSDB record page.
TERRESTRIAL FATE: Based on a classification scheme(1), reported Koc values ranging from 3200 to 7734(2,3) indicate that difenoconazole is expected to be slightly mobile to immobile in soil(SRC). Volatilization of difenoconazole from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 8.9X10-12 atm-cu m/mole(SRC), based upon its vapor pressure, 2.5X10-10 mm Hg(4), and water solubility, 15 mg/L(4). Difenoconazole is not expected to volatilize from dry soil surfaces(SRC) based upon its vapor pressure(4). Slow biodegradation of difenoconazole may occur under certain conditions; however, may be limited by its bioavailability(4,5).
AQUATIC FATE: Based on a classification scheme(1), reported Koc values ranging from 3200 to 7734(2,3) indicate that difenoconazole is not expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is not expected(4) based upon an estimated Henry's Law constant of 8.9X10-12 atm-cu m/mole(SRC) derived from its vapor pressure, 2.5X10-10 mm Hg(5), and water solubility, 15 mg/L(5). According to a classification scheme(6), a BCF of 330(7), suggests that bioconcentration in aquatic organisms is high(SRC). Slow biodegradation of difenoconazole may occur under certain conditions; however, may be limited by its bioavailability(5,8).
ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), difenoconazole, which has a vapor pressure of 2.5X10-10 mm Hg at 25 °C(2), is expected to exist solely in the particulate phase in the ambient atmosphere. Particulate-phase difenoconazole may be removed from the air by wet and dry deposition(SRC). Difenoconazole contains chromophores that absorb at wavelengths >290 nm(3) and, therefore, may be susceptible to direct photolysis by sunlight(SRC).
In 2010 residues of difenoconazole in rice fields were examined in samples from Guangxi, Hubei and Zhejiang province; the half life for difenoconazole in rice plants ranged from 1.39 to 2.59 days; additional half-lives reported for difenoconazole in the study were as follows: in Chinese cabbage 6.6 to 7.8 days, in apples 26.2 to 81.7 days, and in chili fruit 4.68 to 8.09 days. Residues of difenoconazole were undetectable in rice hull and husked rice samples 30, 40, and 50 days after application of pesticide at 90 to 135 grams a.i./ha(1).
A variety of bananas used in several field studies of difenoconazole, at an application of 800 g a.i./ha, had residues of this chemical ranging from <0.02 ppm to 0.13 ppm in whole banana samples, less than 0.02 ppm in banana pulp, and less than 0.02 ppm to 0.25 ppm in banana peel. Field studies conducted in several US states examined residues in wheat grain resulting in residue concentrations less than 0.01 ppm(1).
In an FDA total diet study analyzing foods in 4 market basket studies from the fiscal year 2012, difenoconazole was detected in 20 of 159 food items considered to be infant and toddler foods at a range of 0.0001 to 0.0009 ppm and in 47 of 912 food items other than infant and toddler foods at a range of 0.0001 to 0.006 ppm(1). In an FDA total diet study analyzing foods in 4 market basket studies from the fiscal year 2013, difenoconazole was detected in 73 of 1,070 food items at a range of 0.0001 to 0.005 ppm(2).
IDENTIFICATION AND USE: Difenoconazole is a white crystalline solid. It is used as fungicide, insecticide, seed treatment/protectant. HUMAN EXPOSURE AND TOXICITY: Harmful if inhaled or absorbed through skin. Causes moderate eye irritation. It did not cause chromosomal aberrations in human lymphocytes. One case of allergic reaction to a formulated product was reported. ANIMAL STUDIES: Difenoconazole was moderately and transiently irritating to the eyes of rabbits. It was very slightly and transiently irritating to the skin of rabbits. Difenoconazole was considered to be essentially non-toxic when applied topically under occlusion to intact rabbit skin. In rats treated dermally for 28 days there was an increased incidence of minimal centrilobular hepatocellular hypertrophy in males and females at 1000 mg/kg bw. In the thyroid, the incidence of minimal to moderate severity grades of hypertrophy of the follicular epithelium was slightly increased in the group of rats at 1000 mg/kg bw. The liver appeared to be the target organ for toxicity. There was no evidence for carcinogenicity or oncogenicity in rats. There were no indications of embryotoxicity, fetotoxicity or teratogenicity at a dose up to 75 mg/kg bw per day in rabbits. There were no indications of embryotoxicity or teratogenicity at any dose up to 200 mg/kg bw in rats. Microscopic examination of the central and peripheral nervous system of rats showed no effects of treatment with difenoconazole at dietary concentrations of up to 1500 ppm in males or females. Difenoconazole did not induce gene mutations in either bacterial cells or cultured mammalian cells. ECOTOXICITY STUDIES: In zebrafish experiments, a large suite of symptoms was induced in embryonic development by different dosages of difenoconazole, including hatching inhibition, abnormal spontaneous movement, slow heart rate, growth regression and morphological deformities. Exposure to difenoconazole could alter thyroid hormone levels and gene transcription in zebrafish larvae, indicating endocrine disruption. Genes related to hatching, retinoic acid metabolism and lipid homeostasis were up-regulated by difenoconazole in zebrafish embryos. Difenoconazole exposure could also change lipid metabolism and profiles in marine medaka (Oryzias melastigma). Difenoconazole inhibited the respiration of mitochondria of the flight muscles of bumblebee.
/BIRDS and MAMMALS/ Pesticide coated seeds are commonly used in agriculture, and may be an important source of food for some birds in times of scarcity, as well as a route of pesticide ingestion. We tested the lethal and sub-lethal effects of treated seed ingestion by the red-legged partridge (Alectoris rufa), a game bird of high socio-economic value in Spain. One year-old partridges (n = 42 pairs) were fed for 10 days in spring (prior to breeding) with wheat treated with difenoconazole (fungicide), thiram (fungicide) or imidacloprid (insecticide), using two doses for each pesticide (the one recommended, and its double to represent potential cases of abuse of pesticides). We investigated the direct and indirect effects on the body condition, physiology, immunology, coloration and subsequent reproduction of exposed partridges. For the latter, eggs were collected, measured and incubated and the growth and survival of chicks were monitored. Thiram and imidacloprid at high exposure doses produced mortalities of 41.6 and 58.3 %, respectively. The first death was observed at day 3 for imidacloprid and at day 7 for thiram. Both doses of the three pesticides caused sublethal effects, such as altered biochemical parameters, oxidative stress and reduced carotenoid-based coloration. The high exposure doses of imidacloprid and thiram also produced a decrease in cellular immune response measured by the phytohemagglutinin test in males. Bearing in mind the limitation of the small number of surviving pairs in some treatments, we found that the three pesticides reduced the size of eggs and imidacloprid and difenoconazole also reduced the fertilization rate. In addition, both thiram and imidacloprid reduced chick survival. These experiments highlight that the toxicity of pesticide-treated seeds is a factor to consider in the decline of birds in agricultural environments.
/AQUATIC SPECIES/ Zebrafish, during embryo, larvae and adult stages were selected to investigate the potential environmental risk and aquatic toxicity of a widely used fungicide, difenoconazole. In addition to mortality, embryo development endpoints, teratogenic effects and behavior abnormity were measured. Finally, the developmental parameters of the adult fish were assessed after 14 days' exposure. This study concluded that the acute toxicity of difenoconazole to the three phases of zebrafish were larvae (1.17 mg/L) > adult fish (1.45 mg/L) > embryo (2.34 mg/L). A large suite of symptoms was induced in embryonic development by different dosages of difenoconazole, including hatching inhibition, abnormal spontaneous movement, slow heart rate, growth regression and morphological deformities. 0.50 mg/L of difenoconazole could cause significant body color blackening and decrease in the heart rate of zebrafish larvae over 24 hr. In addition, 0.25 mg/L of difenoconazole apparently inhibited the growth weight of adult zebrafish measured after 14 days' exposure.
/AQUATIC SPECIES/ ... To investigate the effect of difenoconazole on cholesterol content and related mechanism, adult zebrafish were exposed to environmental related dosage (0.1, 10 and 500 ug/L) difenoconazole. The body weight and hepatic total cholesterol (TCHO) level was tested at 7, 15 and 30 days post exposure (dpe). The expressions of eight cholesterol synthesis genes and one cholesterol metabolism gene were assessed via Quantitative PCR method. The significant decrease of TCHO level in male zebrafish liver was observed at 15 and 30 dpe, which was accompanied by apparent hepatic cholesterol-genesis genes expression decline. In comparison with males, female zebrafish showed different transcription modification of tested genes, and the cholesterol content maintain normal level during the whole exposure.
Metabolism studies conducted with tomoatos, wheat, potatoes, grapes, and oilseed rape indicated that difenoconazole was the major residue found on these plants (fruits, seeds, and foliage) 7 to 40 days after the final application of this chemical(1).
EPA has released the Interactive Chemical Safety for Sustainability (iCSS) Dashboard. The iCSS Dashboard provides an interactive tool to explore rapid, automated (or in vitro high-throughput) chemical screening data generated by the Toxicity Forecaster (ToxCast) project and the federal Toxicity Testing in the 21st century (Tox21) collaboration. /The title compound was tested by ToxCast and/or Tox21 assays/[USEPA; ICSS Dashboard Application; Available from, as of December 8, 2016: http://actor.epa.gov/dashboard/]
The mobility of difenoconazole was examined using soil thin layer chromatography with a silt loam containing 2% organic matter; results indicated that this chemical will be essentially immobile in soil(1). Difenoconazole has a reported log Koc = 3.5 (Koc = 3200)(2). Reported adsorption coefficients for difenoconazole in agricultural sand, sandy loam soil, silt loam soil, and silty clay loam soils, are 3866, 3470, 7734, and 7734, respectively(3). According to a classification scheme(4), these Koc values suggest that difenoconazole is expected to be slightly mobile to immobile in soil(SRC).
/SIGNS AND SYMPTOMS/ Harmful if inhaled or absorbed through skin. Causes moderate eye irritation.
/GENOTOXICITY/ /Two/ studies on chromosomal aberrations were conducted ... in human lymphocytes. ... The two studies ... gave unambiguous negative results
/ALTERNATIVE and IN VITRO TESTS/ Various pesticides known or suspected to interfere with steroid hormone function were screened in H295R cells for effects on catalytic activity and mRNA expression of aromatase. ... Various imidazole-like fungicides were aromatase inhibitors. Imazalil and prochloraz were potent mixed inhibitors (K(i)/K(i)(') = 0.04/0.3 and 0.02/0.3 uM, respectively), whereas propiconazole, difenoconazole, and penconazole were less potent competitive inhibitors (K(i) = 1.9, 4.5, and 4.7 uM, respectively. ...
/OTHER TOXICITY INFORMATION/ Monthey, Switzerland; reporting period, 1992 until December 2002. Difenoconazole had been handled since 1992 in three buildings, with an estimated 5300 tons being produced over the decade. In 2002, about two thirds of the product was handled and packed as powder. The remaining one third was used in two premixes, which were either formulated in Monthey or sent in bulk to Aigues Vives, France. The exact number of people potentially in contact with the material was unknown, but it was estimated that "several hundred" temporary workers had been involved with difenaconazole over the 10-year period. No adverse health effects had been recorded within the three buildings concerned or within the medical service based at Monthey.
For more Human Toxicity Excerpts (Complete) data for Difenoconazole (8 total), please visit the HSDB record page.
Slow biodegradation of difenoconazole may occur under certain conditions; however, biodegradation may be limited by its bioavailability. Pure culture degradation of structurally similar diaryl ether pesticides and halogenated diphenyl ethers has been reported, although several dead-end metabolites may inhibit complete mineralization(1). In addition, it has been postulated that the bioavailability of diaryl ether pesticides, such as difenoconazole, decreases under the influence of sunlight as the production of polymeric material and formation of bound residues from activated derivatives occurs(1). In addition, structurally similar pyrethroids undergo photodecarboxylation which limits bioavailability for this class of pesticides(1). In water-sediment systems, rapid dissipation from water was reported for difenoconazole, half-life = 1 to 3 days, while slow degradation from the system was reported, half-life = 8 months(2). Aerobic soil metabolism half-lives ranging from 175 to 1600 days have been reported(3).
SOIL: In 2010 residues of difenoconazole in rice fields were examined in samples from Guangxi, Hubei and Zhejiang province; residues of difenoconazole were undetectable in paddy soil samples 30, 40, and 50 days after application of pesticide at 90 to 135 grams a.i./ha(1).
Tolerances are established for residues of difenoconazole, including its metabolites and degradates, in or on the commodities in the following table. Compliance with the tolerance levels specified below is to be determined by measuring only difenoconazole, 1-[2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazole, in or on the following raw agricultural commodities:[Table#8407]
Tolerances are established for residues of difenoconazole, including its metabolites and degradates, in the commodities in the table below. Compliance with the tolerance levels specified below is to be determined by measuring the sum of difenoconazole, 1-[2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-1,3-dioxolan-2-ylmethyl]-1H-1,2,4-triazole, and its metabolite, CGA-205375, 1-[2-chloro-4-(4-chloro-phenoxy)phenyl]-2-[1,2,4]triazol-1-yl-ethanol, calculated as the stoichiometric equivalent of difenoconazole, in the following commodities:[Table#8408]
New Active Ingredients ... includes chemicals not previously registered as pesticides, as well as pesticide active ingredients initially registered after November 1, 1984 and that currently have active product registrations. By law, these pesticides must meet new safety standards, such as those described in the Food Quality Protection Act of 1996 and, if new safety standards are met, will be reviewed again on a 15-year cycle. Difenoconazole is designated by EPA as a New Pesticide Active Ingredient. Active Ingredient Number: 128847; Type of Pesticide: conventional - fungicide; Use Site: food use/wheat grain; Year: 1994.
The major steps of the metabolism of difenoconazole in the rat were deduced to involve hydrolysis of the ketal in difenoconazole, resulting in CGA 205375 (1-[2-chloro-4-(4-chloro-phenoxy)-phenyl]-2- (1,2,4-triazol)-1-yl-ethanol), with the ketone CGA 205374 (1-(2-chloro-4-(4-chloro-phenoxy)-phenyl)- 2-(1,2,4-triazol)-1-yl-ethanone) as a postulated but not identified intermediate, and hydroxylation on the outer phenyl ring of the parent (hydroxy-CGA 169374) and in CGA 205375 (hydroxy-CGA 205375). As a minor process, cleavage of the alkyl chain between the triazole and the inner phenyl ring occurs, resulting in a hydroxyacetic acid (NOA 448731) or CGA 189138 (2-chloro-4-(4-chlorophenoxy)-benzoic acid) and free triazole. Sulfate conjugates were identified for CGA 205375 and for hydroxy-CGA 205375.
Dissipation of fungicide difenoconazole (3-chloro-4-[(2RS,4RS;2RS,4SR)-4-methyl-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]phenyl 4-chlorophenyl ether) was studied following its application on apples intended for production of baby food. The apples (varieties: Jonagold Decosta, Gala and Idared) were sprayed with the formulation to control pathogens causing fungal diseases: powdery mildew (Podosphaera leucotricha ELL et Ev./Salm.) and apple scab (Venturia inaequalis Cooke/Aderh.). A validated gas chromatography-based method with simultaneous electron capture and nitrogen phosphorus detection (GC-ECD/NPD) was used for the residue analysis. The analytical performance of the method was highly satisfactory, with expanded uncertainties 19% (a coverage factor, k = 2, and a confidence level of 95%). The dissipation of difenoconazole was studied in pseudo-first-order kinetic models (for which the coefficients of determination, R2, ranged between 0.880 and 0.977). The half-life of difenoconazole was 12-21 days in experiments conducted on three apple varieties. In these experiments, the initial residue levels declined gradually and reached the level of 0.01 mg/kg in 50-79 days. For the residue levels to remain below 0.01 mg/kg (the maximum acceptable concentration for baby foods), difenoconazole must be applied approximately 3 months before harvest, at a dose of 0.2 L/ha (50 g of an active ingredient per ha).
A single oral dose of [(14)C-phenyl]difenoconazole at 0.5 mg/kg bw was rapidly and almost completely absorbed by male and female rats. A single oral dose of [(14)C-phenyl]difenoconazole at 300 mg/kg bw was less extensively absorbed since bile-duct cannulated male and female rats excreted 17% and 22%, respectively, of the dose in feces. Maximum blood concentrations were reached within 2 hr, followed by a rapid decline for the lower dose and after approximately 4 hr, with an initial slow decline up to 24 hr, for the higher dose, after which the rate of decline was similar to the lower dose. In females the difference in area under the blood concentration-time curve (AUC) measurements between the lower and higher doses matched the dose differential, while in males the AUC differential was 400-fold. The systemic dose was eliminated predominantly via bile where it accounted for 73% of the administered dose (0.5 mg/kg bw) in males and 76% in females. Urinary excretion by bile-duct cannulated rats accounted for 14% of the administered dose in males and 9% in females, with fecal excretion representing less than 4% of the dose and thereby confirming the almost complete absorption at the lower dose. When bile from male rats at 0.5 mg/kg bw was administered intraduodenally to other bile duct cannulated rats, 80% of the dose was re-eliminated via the bile and just 4% in the urine, thereby demonstrating enterohepatic recirculation. Bile was also the major route of elimination at 300 mg/kg bw, accounting for 56% of the administered dose in males and 39% in females, while urinary excretion represented only 1% of the dose. In non-cannulated male and female rats given a single oral dose of [(14)C-phenyl] difenoconazole or [(14)C-triazole]difenoconazole at 0.5 mg/kg bw, 13-22% of the administered dose was excreted in the urine and 81-87% in the feces. In non-cannulated male and female rats given a single oral dose of [(14)C-phenyl]difenoconazole or [(14)C-triazole]difenoconazole at 300 mg/kg bw, 8-15% of the administered dose was excreted in the urine and 85-95% in the feces. There was no pronounced difference in excretion profiles, either between the sexes or between the two radiolabelled forms at either dose. When a similar dose of [(14)C-phenyl]difenoconazole or [(14)C-triazole]difenoconazole was given to rats pre-treated with 14 daily oral doses of unlabelled difenoconazole at 0.5 mg/kg bw, there was neither a sex difference nor any marked difference in excretion profiles from the rats with no pre-treatment. The excretion data for rats at 0.5 mg/kg bw showed that while enterohepatic recirculation was evident, biliary metabolites were largely excreted in the feces. At the lower dose, the half-life of excretion was approximately 20 hr. At 300 mg/kg bw, more of the administered dose was excreted in the urine by noncannulated rats than by bile-duct cannulated rats, apparently after reabsorption and further metabolism of some biliary metabolites; however, the predominant route of excretion of biliary radioactivity was again in feces, as observed at the lower dose. At the higher dose, the half-life of excretion was approximately 33-48 hr. At both doses, elimination kinetics were thus independent of sex and radiolabel position.
The concentration of radiolabel in the blood reached a maximum concentration (Cmax) at 2 hr after oral administration in male rats at 0.5 mg/kg bw and declined rapidly thereafter. The AUC up to 168 hr after administration was 6.19 ug equivalent/hr per mL. Tmax was shorter in females than in males and Cmax and AUC in females reached only about 50% of the respective values in males. The disappearance of radioactivity in female rats was slightly faster than in male rats. Tissue depletion results showed that at 2 hr and 24 hr after a dose of [(14)C-phenyl]difenoconazole at 0.5 mg/kg bw, only in the liver and kidney were concentrations consistently higher than those in plasma for both sexes. Consistent results were observed in whole-body autoradiography sections of similarly-dosed male rats, since at 2 hr and 24 hr after dosing most of the radioactivity was present in the gastrointestinal tract contents and in bile, with lower concentrations in the liver and kidneys. Other tissues with concentrations initially higher than in plasma were adrenal glands in both sexes and Harderian glands and adipose tissue in females; however, these concentrations declined rapidly. After 168 hr, [(14)C-phenyl]difenoconazole residues in tissue were very low, with only fat showing concentrations comparable to those present in plasma, while all tissue residues of [(14)C-triazole]difenoconazole were either below the limit of detection or below the limit of quantification. For both radiolabelled forms of difenoconazole, residues in female tissues also tended to be slightly lower than those in males and pre-treatment with unlabelled test substance had no effect on tissue distribution.
Tissue depletion results showed that at 4 hr after a dose of [(14)C-phenyl]difenoconazole at 300 mg/kg bw, most tissue concentrations were similar to or higher than those in plasma in both sexes. The highest tissue concentrations were present in fat in both sexes, with progressively lower concentrations in the liver, Harderian glands, adrenal glands, kidney and pancreas. In all other tissues that initially showed concentrations higher than those in plasma concentrations declined rapidly by 48 hr after dosing and by 168 hr all tissue residues of [(14)C-phenyl] difenoconazole had declined markedly, only fat showing residues that were higher than in plasma. Tissue residues of [(14)C-triazole]difenoconazole were significantly lower than those of [(14)C-phenyl]difenoconazole residues and by 168 hr were measurable only in the liver. Measurements in the contents of the gastrointestinal tract were consistent with the observed absorption and elimination profiles.
After 14 days of [4-chloro-phenoxy-U-(14)C]difenoconazole at a dose of at 0.5 mg/kg bw per day, the absorbed radiolabel was rapidly and almost completely excreted, predominantly via the feces. More than 90% of the total administered radiolabel was excreted within 24 hr after the last dose and 98.5% of the total radiolabel was recovered within 7 days. At that time, less than 0.5% of the administered dose remained in the tissues and carcass. Metabolite profiles in the urine and feces were qualitatively similar at each time-point, although small quantitative differences were observed after the administration of single and multiple oral doses. Concentrations of radioactive residues reached a plateau in most tissues after 7 days. Residue concentrations increased with continued dosing in liver, kidneys, fat and pancreas and did not reach a plateau during the dosing period; however, it was estimated that residue concentrations would reach a plateau within 3 weeks. The depletion of radioactive residues from tissues was moderately fast. Assuming first-order kinetics and monophasic depletion kinetics for the depuration of radiolabel from tissues, the half-lives ranged typically from 4-6 days. Depletion was more rapid in the liver, kidneys and pancreas, with half-lives of 1-3 days, and slower in fat, with a half-life of 9 days. Experiments with position-specific radiolabelled compounds demonstrated that the highest tissue concentrations were found in the liver for the triazole label, and in fat and plasma for the phenyl label. Residues from the triazole-labelled compound were significantly less than those from the phenyl-labelled compound. Tissue residues in females were slightly less than in males. Multiple pre-treatment with unlabelled difenoconazole had no effect on tissue distribution.
Studies of dermal penetration in rats given difenoconazole as an application to the skin in vivo and studies with rat and human skin in vitro were conducted using non-radiolabelled difenoconazole (purity, 99.3%) and [triazole-U-(14)C]difenoconazole. The absorption, distribution and excretion of radioactivity was studied in male HanBrlWIST (SPF) rats after a single dermal administration of (14)C-labelled difenoconazole mixed with the nonlabelled difenoconazole formulated as SCORE 250 EC. At the highest dose, the specific activity was 54 kBq/mg (1.5 uCi/mg). For the highest dose, difenoconazole was dissolved in blank formulation at a concentration of 250 g/L, representing the undiluted product. For the intermediate and lowest dose, this formulated material was mixed with water in a ratio of 1:200 (w/v) and 1:5000 (w/v), respectively. The applied nominal doses were 0.5, 13 and 2600 ug/sq cm and these were left in place for 6 hr. The determination of dermal absorption at the highest dose was repeated in a separate experiment, using an application of 2400 ug/sq cm. ... At the lowest, intermediate and highest doses, respectively, systemic absorption within 6 hr was 15.3%, 7.5% and 7.1% and the penetration rates was 0.013, 0.162 and 30.4 ug/sq cm per hr. The ratios of these penetration rates, i.e. 1:12:2400 were proportional to the application concentrations, i.e. 1:26:5100. There was, however, a substantial variation in the data that was attributed to the irritancy of the formulation vehicle, SCORE 250 EC; this resulted in a broad range of individual values for dermal absorption of up to 45% of the administered dose. For the study in rats in vivo, in a worst-case scenario the mean dermal absorption values at the lowest intermediate and highest doses, respectively, were 37.6%, 14.6% and 10.6%. Nevertheless, concentrations of residues in the blood were generally very low: the highest concentrations (as difenoconazole equivalents) were 0.01 ug/mL and 0.26 ug/mL at the intermediate and highest doses, respectively, 6-8 hr after appliciation. The penetration of non-radiolabelled difenoconazole (purity, 99.3%) and [triazole-U-14C] difenoconazole through isolated rat and human epidermal membrane preparations in vitro after stripping the stratum corneum from skin was determined after an exposure of 24 hr to difenoconazole at a concentration of 0.05, 1.28 or 250 mg/mL, achieving applications of 0.5, 12 or 2345 ug/sq cm. ... Within 24 hr, the proportions of radiolabel penetrating the membranes at the lowest, intermediate and highest concentrations, respectively, were 71%, 64% and 23% for the preparations of rat skin and 7.6%, 7.0% and 0.7% for the preparations of human skin. Although the studies with human skin in vitro indicated that dermal absorption was approximately 8% (7.6%) for the lowest concentration, if the amount retained in skin is considered as potentially absorbable it increases to 15%. However, the main objective of the comparative studies of rat and human skin in vitro was to evaluate the differences in the percentage actually absorbed, permitting the estimation of an appropriate species ratio. The flux (i.e. rate of penetration under steady-state conditions) at the lowest, intermediate and highest concentrations, respectively, was 0.020, 0.455 and 26.0 ug/sq cm/hr for the rat skin and 0.002, 0.037 and 0.82 ug/sq cm/hr for the human skin. The flux ratios rat:human were therefore about 1:10, 1:12 and 1:32 at the lowest, intermediate and highest concentrations, respectively. Comparison of the penetration rates at the different doses (concentration ratio, 1:25:5000), revealed an increase in the penetration rates of 1:23:1300 for rat epidermal membranes, while the penetration rates for human epidermal membranes revealed a ratio of only 1:24:500.
For difenoconazole (USEPA/OPP Pesticide Code: 128847) ACTIVE products with label matches. /SRP: Registered for use in the USA but approved pesticide uses may change periodically and so federal, state and local authorities must be consulted for currently approved uses./[
Difenoconazole... is a systemic triazole fungicide that controls a broad spectrum of foliar, seed and soil-borne diseases caused by Ascomycetes, Basidiomycetes and Deuteromycetes in cereals, soya, rice, grapes, pome fruit, stone fruit, potatoes, sugar beet and several vegetable and ornamental crops.
Fungicide, insecticide, seed treatment/protectant.
This is a man-made compound that is used as a pesticide.
Difenconazole is produced by ketalization of 2-bromo-2'-chloro-4'-(4-chlorophenyl)acetophenone with 1,2-propanediol, followed by nucleophilic substitution with sodium 1,2,4-triazolide in dimethylformamide under reflux.
Preparation: A. Hubele, P. Riebli, United Kingdom patent 2098607 (1982 to Ciba-Geigy).
The National Pesticide Information Retrieval System (NPIRS) identifies 4 companies with active labels for products containing the chemical difenoconazole. To view the complete list of companies, product names and percent difenoconazole in formulated products click the following url and enter the CAS Registry number in the Active Ingredient field.
Difenoconazole Technical (Syngenta Crop Protection, LLC): Active ingredient: Difenoconazole 95.0%.
Dividend Fungicide (Syngenta Crop Protection, LLC): Active ingredient: Difenoconazole 32.8%.
Dividend XL RTA (Syngenta Crop Protection, LLC): Active ingredient: Metalaxyl-M 0.27%; Difenoconazole 3.21%.
For more Formulations/Preparations (Complete) data for Difenoconazole (31 total), please visit the HSDB record page.
Fungicides
Environmental transformation -> Pesticides (parent, predecessor)
Pesticides -> Fungicides
개요Difenoconazole is a kind of triazole-type fungicide. It is a broad-spectrum triazole fungicide. It takes effect through acting as the inhibitor of sterol 14α-demethylase, blocking the biosynthesis of sterol. Through inhibiting the sterol biosynthesis process, it inhibits the mycelia growth and germination of pathogens by spores, ultimately suppressing the proliferation of fungi. Difenoconazole has been extensively used in a wide range of crops in many countries due to its ability to control various fungal diseases. It is also one of the most important and widely-used pesticides for disease control in rice.
용도Difenoconazole is a fungicide with broad-range activity, protecting yield and quality by foliar application or seed treatment. It provides long-lasting and curative activity against Ascomycetes, Basidiomycetes and Deuteromycetes. It is used against disease complexes in grapes, pome fruit, stone fruit, potatoes, sugar beet, oilseed rape, banana, ornamentals and various vegetable crops. It is also used as a seed treatment against a range of pathogens in wheat and barley.
정의ChEBI: A member of the class of dioxolanes that is 1,3-dioxolane substituted at position 2 by 2-chloro-4-(4-chlorophenoxy)phenyl and 1,2,4-triazol-1-ylmethyl groups. A broad spectrum fungicide with novel broad-range activity used as a spray or seed treatment. It is moderately toxic to humans, mammals, birds and most aquatic organisms.
/AQUATIC SPECIES/ We report here an investigation of the mechanisms contributing to the divergent sensitivity toward the triazole fungicide difenoconazole of zebrafish (Danio reio) during different life stages. Adult and embryonic zebrafish were exposed to three different concentrations of difenoconazole (0.01, 0.5 and 1.0 mg/L). The death rate, bioaccumulation of difenoconazole, oxidative stress parameters and transcription of related genes were tested at 4 and 8 days post-exposure (dpe). The death rate for adult zebrafish was much higher than that of the embryos at an exposure concentration of 1.0 mg/L at both 4 and 8 dpe. The concentrations of difenoconazole in both the embryos and adult fish were similar, except for the group exposed to 0.01 mg/L difenoconazole. A decrease in antioxidant enzyme activities was observed in both the embryos and the livers of adult fish after exposure to difenoconazole. Significant lipid peroxidation was found in the livers of adult fish in all exposure groups at 8 dpe, but was not observed in the treated embryos. The gene transcription response of the embryos toward difenoconazole was different from that in the livers of adult fish at 4 dpe. At 8 dpe, the modification in the transcription of the tested genes in the embryos and adult fish was similar, except for the genes related to the synthesis of sterols.
For more Ecotoxicity Excerpts (Complete) data for Difenoconazole (10 total), please visit the HSDB record page.